# Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

> **NCT00492050** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 46 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Rituximab
- **DRUG:** Valacyclovir

## Key facts

- **NCT ID:** NCT00492050
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2006-08-02
- **Primary completion:** 2021-02-28
- **Final completion:** 2026-06-28
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492050, "Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00492050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*